Item Details
QIAGEN Takeover Proposal Highlights Investment in Life-Sciences Technology
On 21 October, EQT’s acquisition vehicle announced a proposed cash offer for QIAGEN at €46.50 per share, representing an equity valuation of approximately €9.6 billion. QIAGEN develops sample and assay technologies used in molecular testing, but the proposed transaction is a corporate acquisition rather than a new hospital, medical-tourism or clinical-services contract. Healthcare providers and research organisations can explore clinical-data analysis, laboratory analytics and research computing; HPC can support suitable data-intensive workloads, with quotations based on confirmed technical needs.
Get in Touch
We’ll get back to you shortly.